8-K Announcements
6Material company update
May 15, 2026·SEC
Material company update
May 11, 2026·SEC
Material company update
Mar 5, 2026·SEC
aTyr Pharma, Inc.(ATYR)Earnings, Financials & Key Ratios
ATYR•NASDAQ
$0.55
Price updated Jun 27, 2026
AboutaTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.Show more
- Revenue$190K-19.1%
- EBITDA-$76M-14.6%
- Net Income-$74M-15.8%
- EPS (Diluted)-0.80+7.0%
- Gross Margin-717.37%-817.4%
- EBITDA Margin-40038.95%-41.8%
- Operating Margin-40856.32%-41.4%
- Net Margin-39009.47%-43.2%
- ROE-108.11%-35.3%
ATYR Price & Volume
aTyr Pharma, Inc. (ATYR) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Outpace Liquidity Runway
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Binary clinical trial failure
"aTyr Pharma remains a high-risk, clinical-stage biotechnology entity heavily reliant on the successful progression of its EFZO-FIT Phase III trial to justify its current valuation. The company faces a precarious financial outlook characterized by a lack of recurring revenue and a rapidly depleting cash position that necessitates potential dilutive financing. Investors should monitor the firm's ability to manage its $11.7 million debt load while navigating the significant capital intensity required to sustain its research-heavy operations."
Verdict Logic
the company's precarious liquidity position, highlighted by a cash balance of only $10.0 million against consistent quarterly operating losses, suggests an imminent risk of significant shareholder dilution.
ATYR Growth Metrics
aTyr Pharma, Inc. (ATYR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-55.14%
3 Years-73.65%
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-10.43%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM9.88%
Return on Capital
10 Years-63.13%
5 Years-64.95%
3 Years-76.16%
Last Year-96.5%
ATYR Recent Earnings
aTyr Pharma, Inc. (ATYR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 2/12 qtrs (67%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$0.11+31.3%
$0.16
Rev
—
—
Q2 2026
Mar 5, 2026Metric
Actual
Est
EPS
$0.14+22.2%
$0.18
Rev
—
$40,000
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.26-30.0%
$0.20
Rev
$190,000+850.0%
$20,000
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.22-22.2%
$0.18
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.11vs $0.16+31.3% | — |
| Q2 2026 | Mar 5, 2026 | $0.14vs $0.18+22.2% | —vs $40,000 |
| Q4 2025 | Nov 6, 2025 | $0.26vs $0.20-30.0% | $190,000vs $20,000+850.0% |
| Q3 2025 | Aug 7, 2025 | $0.22vs $0.18-22.2% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for aTyr Pharma, Inc. (ATYR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.55 | $53.51M | -0.68 | -19.15% | -39009.47% | -108.11% | — | |
| $30.77 | $3.03B | -5.28 | 20.13% | -91.03% | — | — | |
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -12.02% | — | |
| $303.59 | $6.08B | 49.53 | 60.4% | 55.95% | 16.19% | — | |
| $327.79 | $9.47B | -24.32 | -100% | — | -43.02% | — | |
| $108.12 | $8.83B | -29.30 | -16.72% | -612.17% | -25.02% | — |
Compare ATYR vs Peers
aTyr Pharma, Inc. (ATYR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ATYR SEC Filings & Documents
aTyr Pharma, Inc. (ATYR) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when ATYR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ATYR Frequently Asked Questions
aTyr Pharma, Inc. (ATYR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is aTyr Pharma, Inc.'s revenue?
aTyr Pharma, Inc. (ATYR) reported $0.2M in revenue for fiscal year 2025.
How fast is aTyr Pharma, Inc. growing?
aTyr Pharma, Inc. (ATYR) saw revenue decline by 19.1% over the past year.
Is ATYR profitable?
aTyr Pharma, Inc. (ATYR) reported a net loss of $70.0M for fiscal year 2025.
Dividend & Returns
What is ATYR's return on equity?
aTyr Pharma, Inc. (ATYR) has a return on equity (ROE) of -108.1%. Negative ROE indicates the company is unprofitable.
What is aTyr Pharma, Inc.'s free cash flow?
aTyr Pharma, Inc. (ATYR) had negative free cash flow of $59.3M in fiscal year 2025, likely due to heavy capital investments.